We are live on ! Find out more

2,812 hedge funds and large institutions have $92.5B invested in Pfizer in 2025 Q3 according to their latest regulatory filings, with 203 funds opening new positions, 1,118 increasing their positions, 1,221 reducing their positions, and 153 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 203 | Existing positions closed: 153

21% more funds holding in top 10

Funds holding in top 10: 2935 (+6)

2% more capital invested

Capital invested by funds: $90.8B → $92.5B (+$1.7B)

0% more funds holding

Funds holding: 2,8102,812 (+2)

8% less repeat investments, than reductions

Existing positions increased: 1,118 | Existing positions reduced: 1,221

1.79% less ownership

Funds ownership: 65.64%63.85% (-1.8%)

15% less call options, than puts

Call options by funds: $2.58B | Put options by funds: $3.03B

Holders
2,812
Holders Change
+2
Holders Change %
+0.07%
% of All Funds
36.89%
Holding in Top 10
35
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+20.69%
% of All Funds
0.46%
New
203
Increased
1,118
Reduced
1,221
Closed
153
Calls
$2.58B
Puts
$3.03B
Net Calls
-$450M
Net Calls Change
+$262M
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1601
Addison Capital
Pennsylvania
$683K +$661K +26,789 New
LA
1602
Legacy Advisors
Pennsylvania
$682K +$661K +26,773 New
CFP
1603
Cascade Financial Partners
California
$682K +$2.47K +100 +0.4%
ASC
1604
Atalanta Sosnoff Capital
New York
$682K +$661K +26,763 New
BAAM
1605
Baker Avenue Asset Management
California
$682K +$14.9K +603 +2%
MDA
1606
Minot DeBlois Advisors
Massachusetts
$681K +$6.17K +250 +0.9%
MLL
1607
Moody Lynn & Lieberson
Massachusetts
$680K -$71K -2,877 -10%
KA
1608
Klingman & Associates
New York
$680K +$149K +6,021 +29%
BWM
1609
BCS Wealth Management
Tennessee
$680K -$554K -22,439 -46%
AWAG
1610
ARS Wealth Advisors Group
Florida
$677K +$12.6K +510 +2%
KCM
1611
Kendall Capital Management
Maryland
$676K +$225K +9,115 +52%
NWM
1612
Northcape Wealth Management
New York
$674K +$3.08K +125 +0.5%
TIA
1613
Traphagen Investment Advisors
New Jersey
$673K +$2.29K +93 +0.4%
AHL
1614
Abel Hall LLC
Louisiana
$671K +$10.9K +442 +2%
PAM
1615
Peak Asset Management
Colorado
$670K -$60.6K -2,457 -9%
TCM
1616
Telos Capital Management
California
$670K -$27.7K -1,121 -4%
CRI
1617
Colonial River Investments
Virginia
$670K -$1.73K -70 -0.3%
CCA
1618
Checchi Capital Advisers
California
$668K -$222K -9,011 -26%
BSB
1619
Bangor Savings Bank
Maine
$667K -$81.3K -3,295 -11%
MFS
1620
Mattson Financial Services
Michigan
$665K -$1.09M -44,249 -63%
SIC
1621
Samalin Investment Counsel
New York
$664K -$104K -4,215 -14%
SJIM
1622
St. Johns Investment Management
Florida
$662K -$21.8K -884 -3%
OIM
1623
Orca Investment Management
Oregon
$660K -$1.73K -70 -0.3%
NEPPG
1624
New England Professional Planning Group
Rhode Island
$660K -$55.8K -2,260 -8%
AMBIA
1625
Allen Mooney & Barnes Investment Advisors
Georgia
$659K -$6.02K -244 -0.9%

PFE Hedge Fund Activity: Q3 2025 in Review

2,812 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2025, worth a combined $92.5B — up 1.9% from $90.8B a quarter earlier.

Buyers outnumbered sellers: 203 funds opened new PFE positions and 153 closed out — a net gain of 50 holders — while 1,118 added to existing stakes and 1,221 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $240M. The largest seller was Massachusetts Financial Services, cutting an estimated $441M.

  • 2,812 institutional investors held Pfizer (PFE) as of Q3 2025, up from 2,810 in Q2 2025.
  • Funds reported $92.5B of Pfizer stock for Q3 2025, up 1.9% quarter-over-quarter.
  • 203 funds opened new Pfizer positions in Q3 2025 and 153 closed out, a net change of +50 holders.
  • The largest Pfizer buyer in Q3 2025 was Royal Bank of Canada, an estimated $240M added.
  • The largest Pfizer seller in Q3 2025 was Massachusetts Financial Services, an estimated $441M sold.

Based on aggregated 13F filings for Q3 2025.